Albemarle Corp. vs Danaher Corporation — how do they compare? Albemarle Corp. trades at $131.06 (market cap $15.27B), while Danaher Corporation trades at $206.12 (market cap $145.83B). The key difference: Danaher Corporation is far larger — about 9.6× Albemarle Corp.'s market cap, and Albemarle Corp. pays the higher dividend (1.27%). Which is the better fit depends on your goals.
| ALB | DHR | |
|---|---|---|
Market Cap | $15.27B | $145.83B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $242.05 |
52-Week Low | $72.58 | $161.91 |
Enterprise Value | $17.75B | $168.04B |
Dividend Yield | 1.27% | 0.77% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Danaher (DHR) trades at $207.44, up 1.31% today, near its pivot point of $207. The stock exhibits a bullish technical trend, supported by moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company maintains strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights the acquisition of Masimo and new product launches from its SCIEX unit, signaling growth initiatives.
The outlook remains positive with analyst consensus favoring a Buy rating and a $202.33 price target, though the current price exceeds this. Risks include a high P/E ratio of 37.32 and ongoing legal settlements, but robust cash flow and institutional accumulation provide support. Earnings growth in the biotechnology segment is a key catalyst for further upside.
Trailing returns across standard periods
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →